FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1526363547> ?p ?o ?g. }

• W1526363547 endingPage "283" @default.
• W1526363547 startingPage "275" @default.
• W1526363547 abstract "Ciclosporin has proven to be effective in patients with corticosteroid-refractory ulcerative colitis (UC). When therapy with this drug fails, infliximab can be considered to avoid colectomy. The efficacy and safety of this sequential approach remain unknown.To assess the efficacy and safety profile of treatment with infliximab after failure of ciclosporin in patients with a corticosteroid-refractory flare of UC.Retrospective review of medical records of patients with a corticosteroid-refractory flare of UC who did not respond to ciclosporin and received salvage therapy with infliximab within a month of discontinuing ciclosporin. The severity of the flare and response to the treatment were graded using the Lichtiger index. Cumulative rates of colectomy were calculated using Kaplan-Meier analysis. Cox regression analysis was performed to identify predictors of colectomy. To evaluate the safety profile of this treatment strategy, any adverse event occurring after the first infusion of infliximab was considered.The study population comprised 47 patients with corticosteroid-refractory UC treated with infliximab after failure of ciclosporin. The median baseline Lichtiger index was 13. The mean time from the last ciclosporin dose to the first infliximab infusion was 6 days. After the first infliximab infusion, 13% of patients achieved remission, and 74% partial response. Of the 35 patients who received the third infliximab infusion, 60% achieved remission, and 37% partial response. Fourteen patients (30%) underwent colectomy. The rate of adverse events was 23%. One death occurred in a 40-year-old man who failed ciclosporin and infliximab and underwent surgery 10 days after the first infliximab infusion; he died of nosocomial pneumonia.Treatment with infliximab makes it possible to avoid colectomy in two-thirds of corticosteroid-refractory UC patients in whom ciclosporin fails. However, the rates of adverse events and mortality mean that the decision to administer sequential therapy (ciclosporin-infliximab) should be taken on an individual basis." @default.
• W1526363547 created "2016-06-24" @default.
• W1526363547 creator A5003069390 @default.
• W1526363547 creator A5009437472 @default.
• W1526363547 creator A5009906875 @default.
• W1526363547 creator A5014029646 @default.
• W1526363547 creator A5014918083 @default.
• W1526363547 creator A5015509846 @default.
• W1526363547 creator A5031449754 @default.
• W1526363547 creator A5034116654 @default.
• W1526363547 creator A5037542727 @default.
• W1526363547 creator A5038265124 @default.
• W1526363547 creator A5039571121 @default.
• W1526363547 creator A5052062860 @default.
• W1526363547 creator A5053129179 @default.
• W1526363547 creator A5074679114 @default.
• W1526363547 creator A5077550825 @default.
• W1526363547 creator A5079335072 @default.
• W1526363547 creator A5079734926 @default.
• W1526363547 creator A5085192283 @default.
• W1526363547 creator A5087537356 @default.
• W1526363547 creator A5089741986 @default.
• W1526363547 date "2011-12-05" @default.
• W1526363547 modified "2023-10-16" @default.
• W1526363547 title "Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study" @default.
• W1526363547 cites W135676000 @default.
• W1526363547 cites W1487976653 @default.
• W1526363547 cites W1520076069 @default.
• W1526363547 cites W1593679868 @default.
• W1526363547 cites W1609503004 @default.
• W1526363547 cites W1748466511 @default.
• W1526363547 cites W1987925515 @default.
• W1526363547 cites W1990832865 @default.
• W1526363547 cites W1990951088 @default.
• W1526363547 cites W2001478786 @default.
• W1526363547 cites W2007433561 @default.
• W1526363547 cites W2022808790 @default.
• W1526363547 cites W2030553050 @default.
• W1526363547 cites W2034093184 @default.
• W1526363547 cites W2034502600 @default.
• W1526363547 cites W2063114655 @default.
• W1526363547 cites W2071644653 @default.
• W1526363547 cites W2095492007 @default.
• W1526363547 cites W2099055805 @default.
• W1526363547 cites W2102897127 @default.
• W1526363547 cites W2110407130 @default.
• W1526363547 cites W2112768046 @default.
• W1526363547 cites W2115509137 @default.
• W1526363547 cites W2143710323 @default.
• W1526363547 cites W2161471380 @default.
• W1526363547 cites W2164153707 @default.
• W1526363547 cites W2164180626 @default.
• W1526363547 cites W2169912308 @default.
• W1526363547 cites W2171297959 @default.
• W1526363547 cites W2171789845 @default.
• W1526363547 doi "https://doi.org/10.1111/j.1365-2036.2011.04934.x" @default.
• W1526363547 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22142227" @default.
• W1526363547 hasPublicationYear "2011" @default.
• W1526363547 type Work @default.
• W1526363547 sameAs 1526363547 @default.
• W1526363547 citedByCount "100" @default.
• W1526363547 countsByYear W15263635472012 @default.
• W1526363547 countsByYear W15263635472013 @default.
• W1526363547 countsByYear W15263635472014 @default.
• W1526363547 countsByYear W15263635472015 @default.
• W1526363547 countsByYear W15263635472016 @default.
• W1526363547 countsByYear W15263635472017 @default.
• W1526363547 countsByYear W15263635472018 @default.
• W1526363547 countsByYear W15263635472019 @default.
• W1526363547 countsByYear W15263635472020 @default.
• W1526363547 countsByYear W15263635472021 @default.
• W1526363547 countsByYear W15263635472022 @default.
• W1526363547 countsByYear W15263635472023 @default.
• W1526363547 crossrefType "journal-article" @default.
• W1526363547 hasAuthorship W1526363547A5003069390 @default.
• W1526363547 hasAuthorship W1526363547A5009437472 @default.
• W1526363547 hasAuthorship W1526363547A5009906875 @default.
• W1526363547 hasAuthorship W1526363547A5014029646 @default.
• W1526363547 hasAuthorship W1526363547A5014918083 @default.
• W1526363547 hasAuthorship W1526363547A5015509846 @default.
• W1526363547 hasAuthorship W1526363547A5031449754 @default.
• W1526363547 hasAuthorship W1526363547A5034116654 @default.
• W1526363547 hasAuthorship W1526363547A5037542727 @default.
• W1526363547 hasAuthorship W1526363547A5038265124 @default.
• W1526363547 hasAuthorship W1526363547A5039571121 @default.
• W1526363547 hasAuthorship W1526363547A5052062860 @default.
• W1526363547 hasAuthorship W1526363547A5053129179 @default.
• W1526363547 hasAuthorship W1526363547A5074679114 @default.
• W1526363547 hasAuthorship W1526363547A5077550825 @default.
• W1526363547 hasAuthorship W1526363547A5079335072 @default.
• W1526363547 hasAuthorship W1526363547A5079734926 @default.
• W1526363547 hasAuthorship W1526363547A5085192283 @default.
• W1526363547 hasAuthorship W1526363547A5087537356 @default.
• W1526363547 hasAuthorship W1526363547A5089741986 @default.
• W1526363547 hasBestOaLocation W15263635471 @default.
• W1526363547 hasConcept C121332964 @default.
• W1526363547 hasConcept C126322002 @default.
• W1526363547 hasConcept C141071460 @default.

• next